Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹5 Cr
Revenue (TTM)
₹0 Cr
Net Profit (TTM)
₹0 Cr
ROE
-19 %
ROCE
-3.9 %
P/E Ratio
--
P/B Ratio
0
Industry P/E
44.74
EV/EBITDA
1.4
Div. Yield
0 %
Debt to Equity
4.3
Book Value
₹--
EPS
₹-0.2
Face value
10
Shares outstanding
22,586,350
CFO
₹46.74 Cr
EBITDA
₹-37.84 Cr
Net Profit
₹-88.52 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Celestial Biolabs
| -34.0 | -30.0 | -45.3 | -71.5 | -58.8 | -51.9 | -25.7 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
BSE Healthcare#
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2019
|
2018
|
2017
|
2016
|
2015
|
2014
|
|---|---|---|---|---|---|---|
|
Celestial Biolabs
| -69.5 | -60.8 | 3.4 | -44.9 | -10.9 | 130.2 |
|
BSE Sensex
| 14.4 | 5.9 | 27.9 | 1.9 | -5.0 | 29.9 |
|
BSE Healthcare
| -3.5 | -5.9 | 0.5 | -12.9 | 15.1 | 47.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Celestial Biolabs
|
1.8 | 4.6 | 0.1 | -0.4 | -303.0 | -15 | -- | 0.0 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Manufacture of pharmaceuticals, medicinal chemical and botanical products
Incorporated
1997
Chairman
--
Managing Director
Amit Kumar Singh
Headquarters
Medchal, Telangana
Website
Looking for more details about Celestial Biolabs Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Celestial Biolabs Ltd is ₹1.75 (NSE) and ₹2.02 (BSE) as of 11-Mar-2020 IST. Celestial Biolabs Ltd has given a return of -58.84% in the last 3 years.
Since, TTM earnings of Celestial Biolabs Ltd is negative, P/E ratio is not available.
The P/B ratio of Celestial Biolabs Ltd is 0.05 times as on 11-Mar-2020, a 98 discount to its peers’ median range of 3.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
|
2020
|
0.00
|
1.16
|
|
2019
|
0.00
|
0.13
|
The 52-week high and low of Celestial Biolabs Ltd are Rs -- and Rs -- as of 03-Apr-2026.
Celestial Biolabs Ltd has a market capitalisation of ₹ 5 Cr as on 11-Mar-2020. As per SEBI classification, it is a company.
Before investing in Celestial Biolabs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-0.05
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.